Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nestle's Prospects To Lead OTC Acne Market Gel With Differin Approval

Executive Summary

Differin Gel, the first NDA approved OTC acne treatment, could make Nestle the runaway leader in the market. The Swiss firm's Nestle Skin Health business owns Differin maker Galderma and has a majority stake in a JV marketing Proactiv.


Related Content

Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Differin Gel Enters Changed Marketplace Since Last OTC Acne Drug Approval
Galderma Pioneers NDA Path Into OTC Acne Treatment Market
PDUFA Clock Ticks For FDA Decision On First OTC Acne Ingredient NDA
Rep. Pallone Inquires Into WEN Safety Concerns With Cosmetics Bill In The Works
Nestle Grows Skin Care Footprint, Valeant Gains Antitrust Cover In Derma Deal


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts